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Introduction
Potentially curative therapy is available for most patients with clinically localized prostate cancer. Unfortunately, 30% of these patients will develop metastatic disease, most commonly in the bone marrow (1-3). Diagnostic tests for detecting metastatic disease, including radionucleotide bone scans and prostate-specific antigen (PSA) serum levels, are limited because they cannot detect individual metastatic cells. A bone scan determines whether tumor-caused bone destruction, a late event in the development of metastases, has occurred (4). The PSA serum level is related to tumor burden but, because both the primary tumor and metastases produce PSA, it is impossible to determine what portion of the serum level is secondary to metastatic disease ( 5 ) . Clinical prognostic factors currently available for prostate cancer cannot predict which individual patient is destined to develop metastatic disease. Because there is not curative treatment for metastatic prostate cancer, identifica- at all dilutions. Polymerase chain reaction was more sensitive than immunohistochemistry at the lowest dilutions and lod, p = 0.033). We have evaluated seven patients with prostate cancer for micrometastases. Both of the patients with known metastatic prostate cancer and one of the five patients with clinically localized tumors had micrometastases. Detection of micrometastases may be useful in the staging of prostate cancer. ( J Histochem Cyrdem KEY WORDS: Prostate neoplasms; Immunohistochemistry; Polymerase chain reaction. 1, 1994) tion of patients with undetected metastatic disease before definitive treatment would allow more appropriate therapy to be given.
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Tumor models to investigate novel methods of identlfying smallvolume disease include the detection of micrometastatic disease in breast cancer patients with clinically localized tumors or detection of residual disease in chronic myelogenous leukemia (CML) patients who had an initial complete response after bone marrow transplantation. These tumors have certain common characteristics that make them amenable to early detection of metastatic disease. These include: (a) a tendency for the tumor to metastasize or recur primarily in the bone marrow; (b) the production of a unique protein or antigen that differentiates tumor cells from the surrounding normal cells; and (c) the likelihood that a significant group of patients with clinically localized disease will relapse with metastatic disease (breast cancer) or recur after an initial complete response to therapy (CML). Prostate cancer also exhibits these characteristics. Prostate and breast cancer metastasize primarily to the bone marrow, and CML relapses in the bone marrow after bone marrow transplantation (3,6,7). Finally, approximately 3 0 4 0 % of patients with clinically localized breast or prostate cancer develop metastases, and 20% of patients with CML relapse after bone marrow transplantation (1,2,6,7).
The presence of metastatic cells in the bone marrow of patients with localized breast cancer is associated with known poor prog-nostic factors (8, 9) . However, 3-10% of patients with no evidence of micrometastatic disease in the bone marrow when the primary tumor is resected eventually suffer a relapse (10.11). In addition, in only 10% of patients with micrometastases at the time of surgery will metastatic cells be evident on repeat aspiration, even though many of these patients will develop clinically evident metastatic disease (12). Therefore, more sensitive methods of detecting micrometastases are needed.
We have investigated two methods of detecting micrometastatic disease in the bone marrow: (a) immunohistochemistry and (b) polymerase chain reaction amplification of mRNA sequences (RTPCR). Immunohistochemical identification of micrometastases in breast cancer patients has been performed using monoclonal antibodies (MAb) that recognize cytokeratin (CK) antigens (8, 10, 11, 13, 14) . Because breast and prostate cancer are epithelial tumors, they express CK antigens. Normal bone marrow cells do not express CK antigens, and epithelial cells are not found in the bone marrow of normal volunteers (11, 15 ). In addition, prostate cancer and CML cells produce unique proteins that differentiate them from all other cells. CML produces the bcr/abl mRNA product from a translocation of chromosomes 9 and 22, and prostate cancer produces PSA, a cell surface antigen found only on prostate cells (7, 16) . RTPCR of the bcr/abl mRNA has been used to detect minimal residual disease in patients with CML (17) . To improve the sensitivity of detection of micrometastases, we used RTPCR to detect mRNA sequences unique to epithelial cells (cytokeratin 19) and mRNA sequences specific for prostate cells (PSA) in the bone marrow of patients with prostate cancer. We evaluated immunohistochemistry and RTPCR in a model system using a prostate cancer cell line (LNCAP) admixed with lymphocytes to assess the sensitivity and specificity of these techniques. To determine the clinical usefulness of these techniques, we evaluated the bone marrow of seven patients with prostate cancer for the presence of micrometastases.
Materials and Methods
Human Cell Lines. The LNCAP prostate cancer cell line (American Type Culture Collection; Rockville, MD) was used as the positive control cell. These cells were grown in RPMI 1640 medium at 37'C, supplemented with 10% fetal calf serum, 1% glutamine, penicillin (10 U/ml), and streptomycin (1 mglml). The cells were grown in T-150 flasks, and the medium was changed every 3 days. Cells were obtained by trypsinization when the flasks became 90% confluent.
The myeloid HL.60 cell line (American Type Culture Collection), the pro-erythroblast K562 cell line (American Type Culture Collection), normal peripheral lymphocytes. and normal bone marrow cells were used as negative control cells. The HUO and K562 cells were grown in the same type of culture medium as the LNCAP cells. The normal bone marrow cells and lymphocytes were obtained from the bone marrow transplant unit from donors who demonstrated no evidence of an epithelial malignancy. The lymphocytes and bone marrow samples were suspended in RPMI 1640, layered over a Ficoll-Hypaque solution, and centrifuged at 2000 rpm for 20 min. The cell layer at the interface was collected and washed in PBS. This cell layer contained both mononuclear and epithelial cells, if present in the bone marrow (18) .
Test Dilutions. The LNCAP cells were admixed with lymphocytes and bone marrow cells to make the following dilutions: l l O ' , 1:102, 1:103, 1:104, 1:105, and 1:106 LNCAP:lymphocytes or bone marrow cells. RTPCR was per-formed on dilutions made with both lymphocytes and bone marrow cells. No difference was seen in sensitivity or specificity of the analysis. Immunohistochemistry was performed only on the lymphocyte dilutions because of the large number of cells required (1 x 10' cells/dilution). Control slides made with both lymphocytes and bone marrow cells were used. No difference in staining pattern was seen with either type of dilution.
Patient Samples. We have evaluated seven patients with prostate cancer for micrometastatic disease. Two patients had documented bone metastases by bone scan and five had clinically localized prostate cancer and underwent radical prostatectomy with bilateral pelvic lymph node dissection. The patient samples were analyzed in the same manner as the dilutions, except that RTPCR was performed with the PSA primers only owing to the presence of a pseudogene for CKl9 (see Results). Immunohistochemistry, using the PSA MAb, was performed only on patient samples that were positive on the RTPCR experiment, because of the increased sensitivity of RTPCR to detect micrometastases (see Results).
Monodonal Antibodies. We used the MAb Cam 5.2 (Becton-Dickinson; Mountain View, CA), PSA (Dako; Carpinteria, CA), and LCA (leukocyte common antigen; Dako) for this study. Cam 5.2 is a cocktail of CK MAb to CK 8 and 18. PSA is an MAb to prostate-specific antigen, which reacts with prostatic secretory or ductal epithelium and adenocarcinoma of the prostate (16) . Because the manufacturer recommends using acetone fixative to evaluate cell smears, all smears were fixed in acetone. The LCA antibody will stain lymphoid cells and confirm the antigenicity of the specimen.
Immunopxidase Staining Procedure. One hundred pl of the cell sample (2 million cells) was placed on glass slides, and two-paired smears were made to form a monocellular layer. The slides were air-dried and stored at -70°C. One slide from each sample was stained with DiffQuick stain (Harleco; Gibbstown, NJ) for cytologic examination. Briefly, slides were postfixed in 100% acetone and then rinsed in PBS. Endogenous alkaline phosphatase activity was blocked with a levamisole solution, and nonspecific staining was minimized by incubation with normal goat serum. The excess serum was blotted off, primary antibody was applied, and the slides were incubated for 30 min at 37°C. The slides were then rinsed in an automation buffer and incubated with biotinylated goat anti-mouse IgG for CAM 5.2 and goat anti-rabbit IgG for PSA (Kirkegaard & Perry; Gaithersburg, MD) for 30 min at room temperature (RT). Streptavidin-alkaline phosphatase was applied for 30 min. followed by color development with Histomark Red (Kirkegaard & Perry) for 10 min. The slides were then counterstained. Buffer was substituted for primary antibody in negative controls. When this procedure is used, antigen-positive cells (epithelial cells) stain specifically and can be identified by red staining of the cytoplasm (precipitation of chromogen), whereas nonepithelial cells are negative. After staining, the slides were examined microscopically for the presence of antigenpositive, cells. These slides were screened by one of the authors (ERB).
Oligonucleotide Primers. We determined the oligonucleotide primers and hybridization probes for the CK19, PSA, and actin genes from previously published sequences (19) (20) (21) . Actin was used to c o n f i i that the cDNA reaction had occurred and that a cDNA template was present for amplification, To ensure that contaminating DNA in our mRNA was not amplified, we selected our primers from two different exons with at least one intervening intron for each gene (Figure 1 ). Therefore, if genomic DNA were amplified, the product would be much larger than the expected product from the "A.
The oligonucleotide primers were synthesized in our macromolecular synthesis and analysis facility. Because of the high homology between the PSA gene and the human glandular kallikrein gene, we selected the PSA primers to have significant mismatches with the kallikrein gene (21) .
RNA ExuzCtion. Intact mRNA was extracted by the acid-guanidiniumphenol-chloroform technique (22) . The RNA sample was diluted to 0.5 pgl pl in DEPC-water and stored at -20°C. cDNA Reaction. For the cDNA reaction, we used the reverse PCR kit from Perkin-Elmer (Norwalk, CT). We added 3 pg total RNA, 200 mM each dNTP, 250 pmol random hexamers, 1 U RNAsin, and 2.5 U reverse transcriptase to 60 pl of the PCR/cDNA reaction buffer [ 10 mM Tris-HC1, pH 8.3. 50 mM KCI, 3.5 mM MgC12, and 0.01% (w/v) gelatin]. The same buffer was used for the cDNA reaction and the PCR amplification. We then layered 50 pl of mineral oil (Perkin-Elmer) on top of the reaction mixture and incubated the tube at RT for 10 min to allow the random hexamers to anneal to the RNA template. The mixture was then cycled in a Perkin-Elmer thermocycler at the following temperatures and times: 42*C for 15 min. 99'C for 5 min. and 5°C for 5 min.
PCR Amplification Reaction. The cDNA was subjected to PCR amplification as previously described, with minor modifications (23) . We added 20 pl cDNA mixture, 660 ng each of the oligonucleotide amplimers that flank the 5' and 3' regions of the gene in question (Figure l), and 2.5 U %q polymerase (Perkin-Elmer) to 80 pl of the PCR buffer. Next, 50 pl mineral oil was layered on top of the mixture and the reaction tube was placed in the thermal cycler. The PCR amplification was performed in the following sequence: 94°C for 1 min to denature the DNA, 50-60°C for 1 min to allow the amplimers to anneal, and 72'C for 1 min for DNA polymerization to occur. This cycle was repeated 35 times. The amplification temperatures were optimized for each set of primers: CKl9 60'C; PSA 52'C; and actin 58'c (data not shown).
Analysis of the FCR product. Twenty p1 of the PCR product was analyzed by electrophoresis on a 1.5% agarose gel containing 0.5 pg/ml of ethidium bromide in 1 x TBE buffer (89 mM Tris-borate, 89 mM boric acid, 2 mM E m ) at 65 mA with 1 KB size markers (BRL.; Grand Island, NY) for 3 hr. The presence or absence of an amplified band was identified by UV illumination of the gel, and a Polaroid picture was taken. The gel was then denatured, neutralized, transferred to a Gene Screen plus nylon membrane (NEN Boston, MA) in 10 x SSC (1 x SSC = 0.15 M NaCl and 0.015 M sodium citrate) overnight, and air-dried. The membrane was then pre-hybridized at 42°C for 1 hr in a buffer consisting of 1 M NaCI, 0.1% SDS (NaDodS04), 50% formamide, and 10% dextran sulfate. We end-labeled 50 ng of oligonucleotide probe specific for each ofthe amplified gene products with [jZP]-ATP by T4 kinase to at least lo8 cpm/g of probe. Two x lo6 cpmlml of labeled probe and 100 pglml of denatured salmon sperm were added to the pre-hybridization buffer and the filter was incubated at 42'C for 12-16 hr. After hybridization, the filters were washed twice in 2 x SSC at RT for 30 min, twice in 0.5 x SSC, 0.1% SDS at 60'C for 30 min. and once in 0.1 x SSC, 0.1% SDS at RT for 30 min. The filters were then exposed to Kodak X R film at -7O'C for 5-24 hr.
Sensitivity and SpeciFcity of RTPCR. Each concentration of LNCAP cells was amplified using primers for the PSA, CK19, and actin genes. The positive control was 100% LNCAP cells, and the negative controls were normal bone marrow cells and lymphocytes. To control for a false-negative result due to degradation of mRNA, we split the cDNA reaction mixture from each sample (60 pl) into thirds (20 p1 for each PCR reaction) and amplified them with all three primers. To control against Use-positives, one set of pipettes was used for adding the PCR ingredients and another set for analyzing the product. This protected against contamination of the pre-PCR reaction with amplified products from the post-PCR reaction. In addition, each experiment included samples with no mRNA template to enable us to determine whether PCR contamination had occurred.
Samples were considered positive for LNCAP cells ifthe amplified CK19 or PSA mRNA was identified after hybridization ofthe PCR product with an oligonucleotide probe specific for the amplified gene in question, provided that the negative controls and the samples with no mRNA template were negative. We considered specimens to be m e negatives for LNCAP cells if there was no amplified band for PSA or CKl9 mRNA but the actin mRNA was amplified.
Determining the Sensitivity and Specificity of Immunohistochemical Staining. The positive control slides contained 100% LNCAP cells and the negative control slides containing 100% lymphocytes. The dilutions were considered positive if individual cells revealed positive staining with either CK or PSA antibodies and if light microscopy confirmed that this staining was epithelial in nature, given that the lymphocytes were negative for CK and PSA but positive for the LCA antibody.
Biostatistical Considerations. To determine the sensitivity and specificity of PCR and immunohistochemistry. each dilution of LNCAP cells was tested twice. The samples were blinded to the investigator performing the test. The two lowest dilutions that were positive for LNCAP cells were tested 10 times. Fisher's exact test was used for statistical analysis.
Results
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LNCAP cells showed a strong signal for the PSA sequence and no PCR product in the non-epithelial cells (Figure 2 ). However, with the CKl9 primers, a positive signal was occasionally noted in our negative controls (Figure 3) . Hybridization with the oligonucleotide probe for CK19 confirmed that CK19 sequences were present in some of our negative control samples. We amplified RNA and DNA with the CK19 primers to determine whether complementary sequences were present in DNA. A strong signal at the proper molecular weight for both the DNA and RNA samples was found (data not shown). Because we used primers that were on two different exons, a likely explanation for the presence of CK19 sequences "@in non-epithelial cells is that a pseudogene for CK19 was being amplified. A search of the gene bank library for any DNA CD19complementary sequences revealed a pseudogene for CK19. Greater than 30% homolog mists between the pseudogene and the mRNA. Despite multiple attempts. we were unable to identify a specific set of primers for the CK19 mRNA. Therefore. we treated our RNA samples with DNAse to remove contaminating DNA. As shown in DNAse-treated LNCAP:lymphocyte dilutions, we found that the DNAse treatment often degraded the RNA, which made the samples unreliable. Therefore, we did not perform dilutional assays using the CK19 primers. We performed RTPCR using the PSA primers on LNCAPlymphocyte dilutions. An amplified product for PSA was identified in all of the dilutions down to 1 LNCAP cell/106 lymphocytes (Figure 4) . At this dilution. an amplified product was identified in eight of 10 experiments ( Table 1 ). There were no falx-positive mults. Figure 5 shows an LNCAP/lymphocyte mixture after incubation with CAM 5.2 and PSA MAbs. LNCAP cells could clearly be seen as the dark-staining cells; the background lymphocytes showed no staining. Normal bone marrow cells did not stain with either PSA or CAM 5.2. The intensity of LNCAP cell staining with the CAM 
Immunohistochemistry
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MAb was stronger than that of the PSA MAb, but virtually all of the LNCAP cells stained with both antibodies. In the dilutional experiments, immunohistochemistry correctly identified LNCAP cells in each of the samples down to the IO6 dilution. However. with the CAM 5.2 and PSA MAb. only two and three of 10 samples at the 10" dilution were positive for LNCAP cells. respectively (pX.1) ( Table 1) . At the low5 and dilutions, one or two positive cclls/slidc were identified, supporting the accuracy of our dilutions.
Statistics
Poisson probability would predict that at the lo4 dilution only sevcn of the 10 samples would contain LNCAP cells. Howcvcr, using RTPCR, eight of the 10 10" samples were positive. Because RTPCR cannot be more than 100% sensitive in detecting LNCAP cells. we have assumed that one LNCAP cell was present in each 10" dilution. Table 1 shows the sensitivities of immunohistochemistry and RTPCR at the and LNCAP concentrations. RTPCR was significantly more sensitive than immunohistochemistry at both of these dilutions (p = 0.033).
Patient Samples
Both RTF'CR and immunohistochemistry identified micrometastases in the patients with known metastatic disease ( Figure 6 ). The number of metastatic cells seen by immunohistochemistry was 8 and 20 cellsl106 bone marrow cells, respectively. Of the five patients with clinically localized disease. RTPCR identified micrometastases in one of them. This patient's tumors extended to the surgical margins of resection but there was no evidence of lymph node mctastases. Immunohistochemistry found metastatic cells in this patient (3 cclls/106 bone marrow cells). The primary tumor was pathologically confined to the prostate in the four patients with no evidence of micrometastases (negative RTPCR). The Glcason sum grade was 6 or 7 for the tumors from the five patients with clinically localized disease and Gleason sum 8 for the two patients with metastatic d '
Isease.
Discussion
To improve the detection rate for micrometastases, scveral studies have evaluated the incidence of micrometastases in breast cancer using MAb specific for epithelial cells (8-11.13.14). These studies concluded that micrometastases are present in approximately 20-30% of patients with clinically localized breast cancer. The praence of micrometastases is statistically associated with a variety of poor prognostic factors (8.9). Follow-up studies have shown that patients with micrometastases relapse with distant metastasis carlier than thox without micrometastases (10.11). Approximately 33% of patients with micrometastases relapse. as opposed to relapse rata of 3-15% in patients without micromctastascs.
One study reports that many patients who had micromctastasa at the time of surgery do not have malignant cells in their bone marrow on follow-up examinations (12). Ten percent of the patients with micrometastases at the time of surgery had metastatic cells on repeat aspiration. However, 19% of patients who had a local recurrence, 30% of patients with metastatic disease at sites other than the bone, and 100% of patients with radiologically proven bone metastases had persistent micrometastatic disease in the bone marrow. Interestingly, 27% of patients in whom the primary tumor was left in situ while the patient received neoadjuvant therapy had micrometastases both at the time of diagnosis and 3 months later. This study raises the possibility that many of the cells within the bone marrow at the time of surgery are circulating cells that do not produce metastatic disease. Conversely, it may be that immunohistochemistry is not sensitive enough to detect small numbers of malignant cells after the primary tumor has been removed and the continued shedding of tumor cells has stopped. One study reports using immunohistochemical techniques to detect tumor cells in the bone marrow of patients with prostate cancer. Mansi et al. (24) evaluated 40 patients; of these, 15 had local disease, 15 had metastatic disease, and 10 had benign prostatic hyperplasia (BPH). The authors found metastatic cells in 73% of patients with metastatic disease and in 13% of patients with clinically localized disease. No tumor cells were identified in patients with BPH. The existence of micrometastases did not correlate with the stage or grade of the tumor; however, the number of patients evaluated was small. Long-term follow-up is not available to determine whether these findings have prognostic significance but, of the 11 patients with clinically evident bony metastases and tumor cells in the bone marrow, six had progressive disease, compared with only one of four patients who did not have bone marrow metastases. Of concern is that this technique identified tumor cells in only 73% of patients with known metastatic disease. This relatively low detection rate suggests the need to develop a more sensitive test for identifying micrometastatic disease.
A limitation of immunohistochemical analysis is its lack of sensitivity. Dilutional assays with breast cancer cell lines to determine the sensitivity of immunohistochemical analysis have found that the lowest dilution at which this technique can identify a malignant cell is 1 cancer cell/105 bone marrow cells (9, 14, 25) . At this dilution, immunohistochemistry identified breast cancer cells in only 24% of the slides containing lo6 cells (25) . Using a prostate cancer model, we found that cytokeratin MAb exhibited a stronger staining intensity than PSA MAb, but there was no difference in the detection rate of the prostate cells in any of our dilutions. We were able to reliably identify prostate cancer cells down to a dilution of 1 prostate cancer cell/104 lymphocytes, even though each slide contained 1,000,000 total cells. Below the dilution, only 30% of slides contained identifiable prostate cancer cells. Therefore, improved methods with better sensitivity may better detect micrometastases.
PCR amplification can detect either mRNA sequences that are unique to certain cells or the relative amount of mRNA produced by a cell (26) . Under optimal conditions, there will be 1,000,000 more copies of the specific sequence of concern than were in the original sample. This allows the detection of one target cell from a population of 106-107 background cells (27) . The bcr/abl mRNA has been amplified to detect minimal residual disease in patients with CML after bone marrow transplantation. In a series of sensi-tivity assays using the K562 cell line (which expresses the bcr/abl fragment) diluted with normal lymphocytes, one K562 cell could be detected from a population of lo6 lymphocytes (17, 28) . In no cases did lymphocytes express the bcr/abl fragment; therefore, the specificity was 100%. As seen with the CK19 gene, pseudogenes can cause false-positive results. Therefore, adequate negative controls are needed when RTPCR is used to ensure that the PCR product is from amplified RNA. This includes using samples that do not express the gene in question and are prepared in the same manner as the test samples. In addition, a GeneBank screening of the primers should be done to determine if there is any crossreactivity to other genes.
Because breast and prostate cancer do not exhibit a consistent chromosomal translocation, amplification of genes specific for epithelial cells is required to detect micrometastases. We chose the CK19 gene because it is the most epithelium-specific of all the cytokeratins (29). CK8 and CK18 have been found in non-epithelial cells, including endodermal cells and some mesodermal cells (29). However, the presence of a CK19 pseudogene decreased the specificity of our assay. CK8 and CK18 also have pseudogenes with a high degree of homology. DNAse treatment eliminated the problem of DNA amplification, but we found that DNAse treatment of small quantities of mRNA occasionally degraded the entire sample. However, for epithelial tumors without another specific mRNA sequence, DNAse treatment of bone marrow aspiration samples, followed by RTPCR with CK19 primers, may be worthwhile.
Using primers for PSA, we found that PSA mRNA could easily and reliably be amplified from as few as 1 LNCAP cell/lo6 lymphocytes. This technique is rapid and, unlike immunohistochemistry, it does not rely on a pathologist for cytological discrimination between malignant and non-malignant cells. PSA is an ideal target sequence because it is cell-type-specific and is expressed to a high degree in the target cells. A potential problem of using PSA to detect prostate cancer cells is that when prostate cancer cells become undifferentiated they express less PSA. However, this almost always occurs in patients with hormone-refractory metastatic disease. Even in this situation, it is unclear whether the non-PSAexpressing cells are not making PSA mRNA or whether there is a post-transcriptional modification that prevents the PSA product from being expressed on a cell membrane.
Currently available important prognostic factors for prostate cancer (pathological stage of histological grade of the primary tumor and the lymph node status) are determined only after surgical resection of the primary tumor or after regional lymphadenectomy. Assessment of the bone marrow using RTPCR and immunohistochemistry before definitive therapy for prostate cancer may improve patient selection and decrease morbidity. Therefore, we are currently using RTPCR and immunohistochemistry to evaluate a large number of patients with localized prostate cancer. Our preliminary findings suggest that RTPCR will identify micrometastases in patients with prostate cancer. Both patients with metastatic disease and the one patient with positive surgical margins had micrometastases. A recent study using RTPCR to detect PSA mRNA from the peripheral blood of patients with metastatic prostate cancer found that four of 12 patients had circulating prostate cells (30). We are analyzing the bone marrow because of the high incidence of bone marrow metastases in patients with prostate cancer. In addition, a study using immunohistochemistry reported that only 10% of breast cancer patients with bone marrow micrometastases had metastatic cells in the peripheral blood (13). Because of the greater sensitivity of RTPCR, if the RTPCR analysis is negative we do not perform immunohistochemistry. However, for samples that are positive for RTFCR, we do perform immunohistochemistry to be able to measure the number of micrometastatic cells. Determining the number of micrometastatic cells per lo6 bone marrow cells in patients with localized cancer is a major advantage of immunohistochemistry. One study has show that the number of micrometastatic cells in the bone marrow is an independent predictor of early recurrence in breast cancer patients (10). Because of the difficulty involved in measuring the amount of mRNA by using RTPCR, immunohistochemistry may be important if the primary tumor is in situ, In addition, we will have the ability to perform further studies relating to cell cycle activity and gene expression using double-labeling techniques. We hope that the complementary results of immunohistochemistry and RTPCR will enable us to better stage patients with prostate cancer and decrease the need for unnecessary treatments.
